Product Pathways - MAPK Signaling
PhosphoPlus® ATF-2 (Thr71) Antibody Duet #8220
|Duet Includes||Quantity||Applications||Reactivity||MW (kDa)||Isotype|
|Phospho-ATF-2 (Thr71) (11G2) Rabbit mAb #5112||100 µl||W F||H M R Mk||70||Rabbit IgG|
|ATF-2 (20F1) Rabbit mAb #9226||100 µl||W IP IHC-P||H M R Mk||65 to 75||Rabbit IgG|
Reactivity Key: H=Human M=Mouse R=Rat Mk=Monkey
Species in parentheses are predicted to react based on 100% sequence homology.
PhosphoPlus® Duets from Cell Signaling Technology (CST) provide a means to assess protein activation status. Each Duet contains an activation-state and total protein antibody to your target of interest. These antibodies have been selected from CST's product offering based upon superior performance in specified applications.
The transcription factor ATF-2 (also called CRE-BP1) binds to both AP-1 and CRE DNA response elements and is a member of the ATF/CREB family of leucine zipper proteins (1). ATF-2 interacts with a variety of viral oncoproteins and cellular tumor suppressors and is a target of the SAPK/JNK and p38 MAP kinase signaling pathways (2-4). Various forms of cellular stress, including genotoxic agents, inflammatory cytokines, and UV irradiation, stimulate the transcriptional activity of ATF-2. Cellular stress activates ATF-2 by phosphorylation of Thr69 and Thr71 (2-4). Both SAPK and p38 MAPK have been shown to phosphorylate ATF-2 at these sites in vitro and in cells transfected with ATF-2. Mutations of these sites result in the loss of stress-induced transcription by ATF-2 (2-4). In addition, mutations at these sites reduce the ability of E1A and Rb to stimulate gene expression via ATF-2 (2).
- Abdel-Hafiz, H.A. et al. (1992) Mol. Endocrinol. 6, 2079-2089.
- Gupta, S. et al. (1995) Science 267, 389-393.
- van Dam, H. et al. (1995) EMBO J. 14, 1798-1811.
- Livingstone, C. et al. (1995) EMBO J. 14, 1785-1797.
For Research Use Only. Not For Use In Diagnostic Procedures.